Table 1.
Demographic and clinical data at renal biopsy and over the follow-up in 174 children <18 years old enrolled in the VALIGA cohort
| Clinical data at biopsy | |
| Female gender | 49 (28.16) |
| Age, years | 12.72±3.63 |
| eGFR, mL/min/1.73 m2 | 117.02 (96.17–120) |
| Proteinuria, g/day/1.73 m2 | 0.84 (0.34–2.18) |
| MAP, mm Hg | 87.53±11.35 |
| Biopsy features | |
| M1 | 38 (21.84) |
| E1 | 24 (13.79) |
| S1 | 74 (42.53) |
| T1–2 | 11 (6.32) |
| Follow-up data | |
| Duration of follow-up, years | 4.63 (2.48–7.35) |
| TA MAP, mm Hg | 86.64±8.54 |
| TA proteinuria, g/day/1.73 m2 | 0.56 (0.27–1.02) |
| RASB treatment | 116 (66.67) |
| CsA/IS treatment | 88 (50.57) |
| ΔeGFR, mL/min/1.73 m2 | 2.01±15.38 |
| ΔMAP, mm Hg | −1.29±11.75 |
| ΔProteinuria, g/day/1.73 m2 | −1.31±3.99 |
| Clinical outcomes | |
| Rate of eGFR loss, mL/min/1.73 m2/year | 0 (−1.72 to 0.76) |
| 15-year survival free from combined event | 163 (93.68) |
| TA proteinuria ≤0.5 in patients with baseline proteinuria >0.5 g/day/1.73 | m2 4/53 (7.54) |
Values are n (%), means ± standard deviations, or medians (interquartile ranges). eGFR, estimated glomerular filtration rate; MAP, mean arterial pressure; M1, mesangial hypercellularity (>50 of glomeruli with mesangial hypercellularity); E1, presence of endocapillary hypercellularity; S1, presence of segmental glomerular sclerosis; T1–2, tubular atrophy/interstitial fibrosis in >25% of renal biopsy tissues; TA, time-average; RASB, renin-angiotensin blockade; CsA, cyclosporine A; IS, steroid/immunosuppressive drugs.